Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space

Start-Up Was First To Start A Phase III Trial

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

3d illustration red blood cells circulating in the blood vessels
Anthos's first Phase III trial aims to prevent blood clots in cancer patients • Source: Shutterstock

Anthos Therapeutics Inc. is the first biopharmaceutical firm to take a Factor XI inhibitor into a Phase III clinical trial, putting the company ahead of at least two big pharma competitors hoping to bring novel anticoagulants to market with the potential to prevent blood clots without increasing bleeding risk. CEO John Glasspool told Scrip that Anthos believes its abelacimab will also be the first Factor XI product to market.

Cambridge, MA-based Anthos launched in 2019 with $250m from Blackstone Life Sciences and with a license from Novartis AG...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe

 
• By Elizabeth Cairns

A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?    

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By Kevin Grogan

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.